- ISIN
- US82686Q1013
- CUSIP
- 82686Q101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 8, 2020
Highlights
- Market Cap
- $355.67M
- Enterprise Value
- $349.79M
- EPS (TTM)
- -$2.38
- Total Revenue (TTM)
- $839.00K
- Gross Profit (TTM)
- $667.00K
- EBITDA (TTM)
- -$71.38M
- Year Range
- $4.19 - $8.40
- Target Price
- $57.00
- ROA (TTM)
- -65.18%
- ROE (TTM)
- 151.89%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SLN Performance Chart
Silence Therapeutics plc (SLN) is up 23.9% since the beginning of the year. At $8 per share, SLN is trading 10.4% below its 52-week high of $8. Investors who bought $1,000 worth of SLN shares 5 years ago would now be looking at an investment worth $291.
Loading charts...
Returns By Period
Silence Therapeutics plc (SLN) has returned 23.85% so far this year and 26.55% over the past 12 months.
Silence Therapeutics plc
- 1D
- 8.66%
- 1M
- 21.45%
- YTD
- 23.85%
- 6M
- 16.74%
- 1Y
- 26.55%
- 3Y*
- 4.23%
- 5Y*
- -21.90%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SLN Monthly Returns History
Based on dividend-adjusted daily data since Sep 8, 2020, SLN's average daily return is +0.06%, while the average monthly return is +1.29%. At this rate, an investment would double in approximately 4.5 years.
Historically, 46% of months were positive and 54% were negative. The best month was Nov 2023 with a return of +92.1%, while the worst month was Nov 2024 at -54.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.
On a daily basis, SLN closed higher 43% of trading days. The best single day was Apr 27, 2023 with a return of +34.1%, while the worst single day was Nov 19, 2024 at -36.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.72% | 12.86% | -3.13% | 38.71% | -5.61% | 9.13% | 23.85% | ||||||
| 2025 | -22.53% | -15.57% | -37.33% | 31.21% | 57.84% | -0.68% | 6.21% | -21.92% | 7.90% | 37.96% | -5.87% | -9.79% | -11.63% |
| 2024 | 29.59% | 13.15% | -15.19% | 1.20% | -3.98% | -9.48% | 7.89% | -6.88% | -4.77% | -4.84% | -54.22% | -13.13% | -60.39% |
| 2023 | -14.75% | -9.85% | -47.10% | 8.06% | -20.75% | 3.58% | 8.36% | 49.33% | 10.34% | -31.77% | 92.09% | 34.97% | 13.90% |
| 2022 | -12.10% | -12.86% | 3.83% | -36.00% | -24.10% | 28.39% | -13.92% | -0.88% | -0.74% | 14.80% | 36.11% | -2.74% | -36.17% |
| 2021 | 13.64% | 1.00% | -8.91% | 9.39% | 9.14% | -4.72% | -2.16% | -9.77% | -10.78% | 6.70% | 6.87% | 1.66% | 8.59% |
Benchmark Metrics
Silence Therapeutics plc has an annualized alpha of 4.61%, beta of 0.67, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since September 08, 2020.
- This stock participated in 117.25% of S&P 500 Index downside but only 9.13% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.67 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4.61%
- Beta
- 0.67
- R²
- 0.02
- Upside Capture
- 9.13%
- Downside Capture
- 117.25%
Return for Risk
Risk / Return Rank
SLN ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Silence Therapeutics plc (SLN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SLN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.67 | ||
| Sortino ratioReturn per unit of downside risk | -1.69 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.37 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 0.64 | 2.78 | -2.15 |
| Martin ratioReturn relative to average drawdown | 1.42 | 12.44 | -11.02 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Silence Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Silence Therapeutics plc was 92.31%, occurring on Apr 9, 2025. The portfolio has not yet recovered.
The current Silence Therapeutics plc drawdown is 73.44%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -92.31%Apr 2025 | 3y 9mo | — | 4y 11moJun 2021 - now |
2020 bear market2020 | -23.08%Oct 2020 | 1mo 13d | 12d | 1mo 25dSep 2020 - Nov 2020 |
2021 bear market2021 | -20.24%Apr 2021 | 1mo 29d | 1mo 19d | 3mo 18dFeb 2021 - Jun 2021 |
2020 correction2020 | -16.46%Nov 2020 | 0s | 1mo 7d | 1mo 7dNov 2020 - Dec 2020 |
2021 pullback2021 | -9.17%Jan 2021 | 7d | 10d | 17dJan 2021 - Jan 2021 |
Drawdown Indicators
| SLN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.31% | -56.78% | -35.53% |
Max Drawdown (1Y)Largest decline over 1 year | -41.89% | -9.10% | -32.79% |
Max Drawdown (3Y)Largest decline over 3 years | -91.70% | -18.90% | -72.80% |
Max Drawdown (5Y)Largest decline over 5 years | -92.31% | -25.43% | -66.88% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -73.44% | -1.80% | -71.64% |
Average DrawdownAverage peak-to-trough decline | -49.59% | -10.71% | -38.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.70% | 2.03% | +16.67% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Silence Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Silence Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SLN relative to other companies in the Biotechnology industry. Currently, SLN has a P/S ratio of 282.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SLN
Add Silence Therapeutics plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SLN